The Qiaseq SARS-CoV-2 primer panel and software aim to speed up COVID-19 prevention and treatment by enabling deeper insights into the epidemiology, metatranscriptomics, immune response, and pathways of the novel coronavirus.

The software allows researchers to identify viral genome sequence variation across samples and to visualize strain divergence across populations and geographies using phylogenetic approaches.

Rare immune stem cells could lead to treatments for COVID-19, cancer
Rare stem cells that give rise to neutrophils in human bone marrow could offer a path to developing treatments for diseases that involve the white blood...

Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...

Could COVID-19 end standoff on tests developed in laboratories?
During the COVID-19 pandemic, research and clinical laboratories were working overtime to develop tests that would help them identify and understand SARS-CoV-2,...

An update on RNA extraction kit supply due to COVID-19
The extraordinary demand for COVID-19 polymerase chain reaction testing has strained the production capabilities of vendors in the nucleic acid preparation...